Angiotensin-converting enzyme (ACE) inhibitor (IC50 = 0.022µM) which also inhibits LTA4 hydrolase in a reversible and competitive manner.
Shows antihypertensive and vasodilatory effects
Orally active.
Recently studied as part of COVID-19 compound repurposing.
Solubility & Handling
Solubility overview
Soluble in water (100mM) and in DMSO (100mM)
Storage instructions
+4°C
Storage of solutions
Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Handling
In aqueous solution, Captopril undergoes a free radical dimerisation to form captopril disulfide. To delay oxidation, use a lower pH, degas solution, minimize headspace, increase the concentration or incorporate a chelating agent or antioxidant.
Shipping Conditions
Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use
Effects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY)
Zhang et al (1996) Clin Exp Hypertens 18(2) : 201-26